Naloxone Doesn't Touch It, and It's Already in Minnesota

Xylazine earns nicknames like “tranq” partly because it leaves a signature: the deep, slow-healing wounds that became a visible marker of the adulterant’s spread. Medetomidine, the veterinary sedative now displacing it in parts of the fentanyl supply, doesn’t leave that signature. It’s up to 300 times more potent than xylazine, does not cause the same skin wounds, and — this is the part that should change how every overdose response is handled — naloxone does not reverse its sedation.

A drug this dangerous doesn’t need a visible symptom to be spreading. It just needs nobody watching for the thing that isn’t there anymore.

CDC’s Health Alert Network notice tracks the scale: national medetomidine identifications in seized drug samples rose from 247 in 2023 to 2,616 in 2024 to 8,233 in 2025, with 98 percent of positive samples also containing fentanyl. Its footprint has concentrated in the Northeast (52 percent of identifications) and Midwest (31 percent), with the South and West still comparatively spared — but that geography is shifting. The Spokesman-Review reported this month that DEA agents seized roughly 250 grams of medetomidine-laced fentanyl in Minneapolis over 15 months, plus a pure-medetomidine seizure in St. Louis County — new territory for a drug that was, until recently, a mostly East Coast problem.

“Our concern is if it does start to explode and get more readily available in the fentanyl supply,” DEA agent Rafael Mattei told the paper. Julie Bauch, who works in Hennepin County, put the exhaustion of it in five words: “We’re on medetomidine now; it will change… The cycle doesn’t end.”

What providers and harm reduction workers need from this isn’t alarm, it’s a protocol update: an overdose that doesn’t fully respond to a standard naloxone dose isn’t necessarily a sign the naloxone failed or the dose was too small — it may be a sign medetomidine is in the mix, and the person needs supportive care (airway management, monitoring) that no amount of additional naloxone will provide on its own. Withdrawal from medetomidine also runs more severe and less predictable than xylazine withdrawal. If you’re using in a region that hasn’t reported medetomidine yet, that absence is not the same as safety — it may just mean nobody’s tested for it.